Neoplastic nerve lesions

Patel, Deep K; Gwathmey, Kelly

doi:10.1007/s10072-022-05951-x

Cited by 12 publications

(6 citation statements)

References 245 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Obturator nerve compression in the obturator canal due to pelvic cancer is one instance of this. 14 An obturator mononeuropathy has been linked to various cancers, including lymphoma, pelvic papillary carcinoma, transitional cell cancer of the bladder, and prostate adenocarcinoma. 14 The ulnar nerve at the axilla or elbow, the intercostal nerves between ribs, the sciatic nerve in the pelvis, and the peroneal nerve near the fibular head are other documented locations of malignant compressive mononeuropathies.…”

Section: Discussionmentioning

confidence: 99%

“… 14 An obturator mononeuropathy has been linked to various cancers, including lymphoma, pelvic papillary carcinoma, transitional cell cancer of the bladder, and prostate adenocarcinoma. 14 The ulnar nerve at the axilla or elbow, the intercostal nerves between ribs, the sciatic nerve in the pelvis, and the peroneal nerve near the fibular head are other documented locations of malignant compressive mononeuropathies. 6 , 14 Unfortunately, neoplasms do not rely solely on external bony compression to cause neoplastic mononeuropathies.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Melanoma metastasis to the femoral nerve: a novel case of melanoma masquerading as mononeuropathy. Illustrative case

Guerrero

Taghlabi

Meyer

et al. 2022

Journal of Neurosurgery: Case Lessons

View full text Add to dashboard Cite

BACKGROUND Metastatic cancer may involve the central and peripheral nervous system, usually in the late stages of disease. At this point, most patients have been diagnosed and treated for widespread systemic disease. Rarely is the involvement of the peripheral nervous system the presenting manifestation of malignancy. One reason for this is a proposed “blood-nerve barrier” that renders the nerve sheath a relatively privileged site for metastases. OBSERVATIONS The authors presented a novel case of metastatic melanoma presenting as intractable leg pain and numbness. Further workup revealed concurrent disease in the brain and breast, prompting urgent treatment with radiation and targeted immunotherapy. LESSONS This case highlights the rare presentation of metastatic melanoma as a mononeuropathy. Although neurological complications of metastases tend to occur in later stages of disease after initial diagnosis and treatment, one must remember to consider malignancy in the initial differential diagnosis of mononeuropathy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Melanoma metastasis to the femoral nerve: a novel case of melanoma masquerading as mononeuropathy. Illustrative case

Guerrero

Taghlabi

Meyer

et al. 2022

Journal of Neurosurgery: Case Lessons

View full text Add to dashboard Cite

show abstract

“…The cancer vasculature becomes increasingly heterogeneous as the primary BT progresses and brain metastasis develops. Neuronal viability and vascular function are directly affected by local and distal changes caused by an expanding neoplastic lesion [ 16 ]. Because the vasculature changes during cancer growth, existing vessels must be co-opted, and/or new ones must be created through angiogenesis to meet the nutritional needs of proliferating cancer cells.…”

Section: A Background Search On Brain Cancermentioning

confidence: 99%

Involvement of Resveratrol against Brain Cancer: A Combination Strategy with a Pharmaceutical Approach

et al. 2022

View full text Add to dashboard Cite

A brain tumor (BT) is a condition in which there is growth or uncontrolled development of the brain cells, which usually goes unrecognized or is diagnosed at the later stages. Since the mechanism behind BT is not clear, and the various physiological conditions are difficult to diagnose, the success rate of BT is not very high. This is the central issue faced during drug development and clinical trials with almost all types of neurodegenerative disorders. In the first part of this review, we focus on the concept of brain tumors, their barriers, and the types of delivery possible to target the brain cells. Although various treatment methods are available, they all have side effects or toxic effects. Hence, in the second part, a correlation was made between the use of resveratrol, a potent antioxidant, and its advantages for brain diseases. The relationship between brain disease and the blood–brain barrier, multi-drug resistance, and the use of nanomedicine for treating brain disorders is also mentioned. In short, a hypothetical concept is given with a background investigation into the use of combination therapy with resveratrol as an active ingredient, the possible drug delivery, and its formulation-based approach.

show abstract

“…Malignant tumors, leukemia, and lymphoma have been known to metastasize to the peripheral nervous system [30]. Neoplasms may also metastasize into the brachial plexus or the lumbosacral plexus [31]. Involvement of the peripheral nerves is rare but may occur [30].…”

Section: Neuropathic Pain and Cancermentioning

confidence: 99%

“…Involvement of the peripheral nerves is rare but may occur [30]. Neoplastic nerve lesions are likewise rare but can occur and result in peripheral pain [31]. But one of the main causes of painful peripheral neuropathy in cancer patients remains chemotherapy.…”

Section: Neuropathic Pain and Cancermentioning

confidence: 99%

Sigma Antagonists for Treatment of Neuropathic Pain Syndromes in Cancer Patients: A Narrative Review

Pergolizzi

LeQuang

2022

J. Can. Res. Updates

View full text Add to dashboard Cite

Almost 40% of cancer patients have neuropathic pain or mixed pain with a neuropathic component, which can be intense, debilitating, and challenging to treat. New studies on sigma receptors show these enigmatic ligand-binding protein chaperones may be helpful drug targets for new pharmacologic options to reduce many types of neuropathies, including chemotherapy-induced peripheral neuropathy (CIPN) and other cancer-related neuropathic pain syndromes. Our objective was to review the literature, including preclinical findings, in support of sigma-1 receptor (S1R) antagonists in reducing neuropathic pain and sigma-2 receptor (S2R) agonists for neuroprotection. The mechanisms behind these effects are not yet fully elucidated. The role of S1R antagonists in treating CIPN appears promising. In some cases, combination therapy of an opioid—which is a true analgesic—with a S1R antagonist, which is an anti-hyperalgesic and anti-allodynic agent, has been proposed. Of interest, but not well studied is whether or not S1R antagonists might be effective in treating CIPN in patients with pre-existing peripheral diabetic neuropathy. While neuropathic syndromes may occur with hematologic cancers, the role of S1R agonists may be effective. Sigma receptors are being actively studied now for a variety of conditions ranging from Alzheimer’s disease to Parkinson’s disease as well as neuropathic pain.

show abstract

Neoplastic nerve lesions

Cited by 12 publications

References 245 publications

Melanoma metastasis to the femoral nerve: a novel case of melanoma masquerading as mononeuropathy. Illustrative case

Melanoma metastasis to the femoral nerve: a novel case of melanoma masquerading as mononeuropathy. Illustrative case

Involvement of Resveratrol against Brain Cancer: A Combination Strategy with a Pharmaceutical Approach

Sigma Antagonists for Treatment of Neuropathic Pain Syndromes in Cancer Patients: A Narrative Review

Contact Info

Product

Resources

About